双/多特异性抗体药物差异化研发策略

Differential discovery strategies of bispecific and multi-specific antibody drugs

摘要:

双特异性抗体药物相比于治疗性单克隆抗体药物有效性和安全性更强，逐渐成为新一代的治疗手段。随着基因工程技术的发展和产业的成熟，双/多特异性抗体药物研究数量不断增加，应用范围也在不断拓展，为满足临床需求和创造临床价值奠定了基础。本文综述了双/多特异性抗体药物的研发阶段和适应症、靶点组合、结构形式和作用机制，并探讨了双/多特异性抗体药物研发的关键点和差异化研发策略，有助于创新药物的快速发展，为推动这一类药物的临床转化应用提供了理论支持，并为临床实践提供了更精准和有效的治疗选择。

Abstract:

Bispecific antibody drugs have enhanced efficacy and safety compared with therapeutic monoclonal antibody drugs, gradually becoming a new generation of effective therapies. With the development of genetic engineering and the maturity of the industry, increasing studies have been carried out on bispecific and multi-specific antibody drugs, and the application indications of these drugs are expanding, which lays a foundation for satisfying the clinical needs and creating clinical values. This paper provides a comprehensive review of the development stages, indications, target combinations, structural formats, and mechanisms of bispecific and multi-specific antibody drugs. It also discusses key points and strategies for differentiated drug discovery, facilitating the rapid development of innovative therapies, providing theoretical support for the clinical translation of these drugs, and offering more precise and effective treatment options for clinical practice.